
Long term thinking: ATMPs, from clinical trials to licensed products

Organisation: iMATCH, Manchester University NHS Foundation Trust

Document version number: 1

Date written: November 2019

End user rights:

This document is shared with permission for re-use to distribute, remix, adapt, and build upon the material in any medium or format for non-commercial purposes only, so long as the attributions listed below are given.

Attributions: Name of Organisation; [others as required by Organisation to be listed here]

This document is made available under a Creative Commons Attribution-NonCommercial 4.0 International License as described here:

<https://creativecommons.org/licenses/by-nc/4.0/>

The information, materials and any opinions contained in this document are provided for general information and educational purposes only, are not intended to constitute legal, medical or other professional advice and should not be relied on or treated as a substitute for specific advice

Funded by

Coordinated by

relevant to particular circumstances. Although we make all reasonable efforts to ensure the information is up to date, we make no representations, warranties or guarantees in that regard. In no event shall the creator(s) be liable for any direct, indirect, special, consequential or other claims, losses or damages that are related to the use or reliance whatsoever in the content of the document or any part thereof, except to the extent that such liability cannot be excluded by law. We do not seek to exclude or limit in any way our liability to the user for personal injury or death caused as a result of our negligence or seek to exclude or limit our liability for fraud or fraudulent misrepresentation by us.

We reserve the right to make changes and improvements to any information contained within this document, at any time and without notice. Where this document contains hyperlinks to other websites operated by parties not connected to us, such hyperlinks are provided for your reference only. We do not control such websites and are not responsible for their contents. The inclusion of hyperlinks from this document or the website to such websites does not imply any endorsement of the material on such websites or any association with their operators. We accept no responsibility of any nature whatsoever for linked web sites or any information contained in them.

Long term thinking: Advanced Therapy Medicinal Products. From Clinical Trials to Licensed products.

Melvin C¹, Burgess S¹, Duran-Jimenez B¹

Pharmacy, Manchester University NHS Foundation Trust

Introduction

- The First Gene therapy medicines are licensed in the UK
 - Chimeric antigen receptor T-cells (CAR-T) are NICE approved for NHS use.
 - NHS hospitals will be required to incorporate ATMPs into routine practice.

UK hospital pharmacy departments generally lack the infrastructure to handle advanced therapy medicinal products (ATMPs) from a governance and operational point of view¹. Horizon scanning predicts exponential growth in this area²

Manchester University NHS Foundation Trust (MFT) was one of the 8 (first wave) centres commissioned as an Advance Therapy Treatment Centre (ATTC) to provide CAR-T to adult and paediatric UK patients.

MFT pharmacy division created in collaboration with Clinicians, Stem Cell Lab the Governance infrastructure (policies and procedures) to comply with national regulations and guidelines, in an effort to be commissioned as an ATTC.

Role of Pharmacy




Figure 1: Role of pharmacy: Establishing Governance for a safe ATMP delivery to patients.

Aim

This case study illustrates the processes MFT pharmacy division followed for a successful implementation of governance and operational procedures in line with current regulations, to be commissioned as an ATTC for CAR-T

Method: Identifying actions required for commissioning

Governance, quality and safety gap analyses	<ul style="list-style-type: none">• Performed using current ATMP legislation³ and national guidance.
Audits	<ul style="list-style-type: none">• Of trust governance systems and processes, including clinical settings and the stem cell laboratory (SCL) prior to Joint Accreditation Committee ISCT-Europe & EBMT (JACIE) accreditation.
Pharmaceutical companies	<ul style="list-style-type: none">• Performed audits and delivered specific training for their products.
Collaboration	<ul style="list-style-type: none">• Regular multidisciplinary meetings.• A task and finish group - including clinical/medicines management pharmacists and clinical trials, stem cell lab (SCL). staff.

Results

- A list of Actions were identified:**
- Creation and implementation of an ATMP policy.
 - Oversight of the SCL for licensed products as per current clinical trial processes:
 - Audit to SCL management systems and processes performed by Pharmacy for this purpose and an audit plan was drafted.
 - Consideration to set a technical agreement between pharmacy and the stem cell lab to delegate some activities, which are currently done under section 10 exemption. Roles and responsibilities were agreed with the stem cell lab and pharmacy.
 - An Advance Therapy Assurance Committee was approved to feedback to the Medicines Optimisation Board: Strategic planning priorities established.

MFT successfully received ATTC status in the first wave of commissioned centres.

First Adult Patient was treated in April

First Paediatric patient was treated in May





Figure 2: CAR-T therapy overview.

Risk Assessment



Ref: HSE-SACGM Compendium of guidance part 6

Discussion

With labs and ASUs at capacity, expansion and future proofing are required.

Requirements going forward:

- Careful assessment to anticipate and identify key areas of focus to ensure compliance and patient safety.
- Streamlined and adaptable procedures applicable to all potential ATMP trials.
- Use horizon scanning to predict likely dates of ATMP implementation
- Trust advanced Therapy Assurance group formed reporting to Medicines Optimisation Board

Challenges going forward:

- Horizon Scanning: 30 new ATMPs
- Communication, equipment, data management systems: 30 years
- Capacity and contingency planning.
- Brexit.




Figure 3: UK ATMP trials Growth.

Acknowledgements

ATMP Pan-UK Pharmacy working group, iMATCH, Stem Cell Lab and Specialist Pharmacy Service (SPS)

References

1. Stoner N. Are UK hospital pharmacy departments ready for the rise of gene therapy medicinal products? Expert Opin Biol Ther, 2018; 18 (8): 837-840.
2. Jørgensen J, Mungapen L & Kefalas P. Data collection infrastructure for patient outcomes in the UK – opportunities and challenges for cell and gene therapies launching, J Mark Access. Health Policy, 2019; 7 (1): 1573164.
3. Detela G, Lodge A. EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation, Mol Ther Methods Clin Dev, 2019; 13 (1): 205–232.